Accueil>>Analytical Standards>>Docetaxel-d9

Docetaxel-d9 (Synonyms: DTX-d9, Taxotel-d9)

Catalog No.GC47250

Le docétaxel-d9 (RP-56976-d9) est le docétaxel marqué au deutérium. Le docétaxel (RP-56976) est un inhibiteur de la dépolymérisation des microtubules, avec une IC50 de 0,2μM. Le docétaxel atténue les effets de l'expression des gènes bcl-2 et bcl-xL. Le docétaxel arrête le cycle cellulaire À G2/M et conduit À l'apoptose cellulaire. Le docétaxel a une activité anticancéreuse.

Products are for research use only. Not for human use. We do not sell to patients.

Docetaxel-d9 Chemical Structure

Cas No.: 940867-25-4

Taille Prix Stock Qté
500 μg
354,00 $US
En stock
1 mg
673,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Video

Docetaxel-d9 is intended for use as an internal standard for the quantification of docetaxel by GC- or LC-MS. Docetaxel is a semisynthetic analog of paclitaxel that inhibits microtubule disassembly (IC50 = 0.2 μM) and inhibits cell replication (IC50 = 0.13 μM).1 It has proven more effective than taxol in preventing the proliferation of cancer cells.1,2 Docetaxel has potential applications in breast cancer and hormone-refractory prostate cancer.3,4

1.Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al.Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogueCancer Research514845-4852(1991) 2.Pazdur, R., Kudelka, A.P., Kavanagh, J.J., et al.The taxoids: Paclitaxel (Taxolr) and docetaxel (Taxoterer)Cancer Treatment Reviews19351-386(1993) 3.Mahon, K.L., Henshall, S.M., Sutherland, R.L., et al.Pathways of chemotherapy resistance in castration-resistant prostate cancerEndocrine-Related Cancer18R103-R123(2011) 4.Yao, X., Hosenpud, J., Chitambar, C.R., et al.A phase II study of concurrent docetaxel, epirubicin and cyclophospha-mide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancerJournal of Cancer3145-151(2012)

Avis

Review for Docetaxel-d9

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Docetaxel-d9

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.